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Abstract 
The prevalence of pituitary disease is increasing mainly due to thbecause ofe advances in 
modern imaging techniques and to the an increased awareness amongst the medical 
community. Pituitary tumours constitute 10-–15% of all diagnosed intracranial neoplasms, 
and their clinical manifestations result from local mass effects (mostly neurological, visual, 
hypopituitarism) and/or hypersecretion. Pituitary adenomas are the most common pituitary 
tumours and are clinically are classified as functioning or non-functioning. The majority 
isMost are sporadic, but, in rare cases, they can be related with to hereditary syndromes. 
Other lesions involving the (para)sellar region include inflammatory and infiltrative diseases, 
cysts, primary or metastatic neoplasms, abscesses and internal carotid artery aneurysms. 
The clinical manifestations of hypopituitarism depend mainly on the type, number and 
severity of hormonal deficits. The Establishingment of the diagnosis requires hormonal 
measurements (basal or after dynamic tests), and the management includes relevant 
hormonal replacement and life-long monitoring. 
 
Keywords 
Craniopharyngioma; hypophysitis; hypopituitarism; pituitary adenoma; pituitary apoplexy; 
pituitary incidentaloma; pituitary stalk lesions; Rathke’s cleft cyst 
 
Key points 
• Pituitary adenomas comprise the majority of pituitary tumours, and can be 
functioning or non-functioning. 
• Clinical features of pituitary masses maycan result from local mass effects and/or 
hypersecretion. 
• Sellar or parasellar masses mainly include adenomatous and non-adenomatous 
tumours, inflammatory and infiltrative diseases, cysts, primary or metastatic 
malignancies, pituitary infections and internal carotid artery aneurysms. 
• All patients with pituitary masses should undergo testing for hypopituitarism, and 
for hormonal hypersection (in cases of pituitary adenomas), radiological assessment 
and neuro-ophthalmological evaluation.  
 
Introduction (A) 
The pituitary gland, or ‘hypophysis cerebri’, is considered to be the ‘master gland’ of the 
endocrine system, integrating, together with the hypothalamus, hormonal signals that 
control a plethora of endocrine and metabolic functions.  
The prevalence of pituitary disease is has increaseding in over the last 10 years due 
tobecause of the advances in modern imaging techniques and hormonal measurements, as 
well as due toan the increased awareness and rate of suspicion rate for these disorders 
amongston the part of the medical community. Fortunately, the improvements in pituitary 
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surgery and radiotherapy techniques, combined with the development of medical 
treatments for pituitary tumours and the advances in pituitary hormone replacement 
therapy, have led to more optimal outcomes.  
 
Pituitary anatomy (A) 
The pituitary gland consists of the an anterior lobe (adenohypophysis), the posterior lobe 
(neurohypophysis), and the vestigial intermediate lobe. It lies at the base of the brain in the 
sella turcica, within the sphenoid bone, and is overlain by the dural sellar diaphragm, 
through which the pituitary stalk connects to the median eminence of the hypothalamus. 
The sellar diaphragm also protects the pituitary from compression by the cerebrospinal fluid 
(CSF). In both sides of the sella turcica, and lateral and superior to the sphenoid sinus, are 
the cavernous sinuses, in which; the cavernous segments of the internal carotid arteries and 
the cranial nerves III, IV, and VI are located in these. The optic chiasm is anterior to the 
pituitary stalk, and typically sits 5-–10 mm above the sellar diaphragm.  
The pituitary measures approximately 13 mm transversely, 9 mm antero-posteriorly, and 
6-–9 mm vertically, and in adults it weighs around 600 mg (range 400-–900 mg). However, 
the size and the volume of the gland change in different situations:; the pituitary increases 
during pregnancy to almost twice its normal size, whilst whereas it decreases in older 
people.  
 
Anterior lobe (adenohypophysis) (B) 
The anterior lobe constitutes nearly 80% of the gland’s mass and comprises five hormone-
secreting cell types (Table 1): 
• somatotrophs, which produce and secrete growth hormone (GH) 
• lactotrophs, which produce and secrete prolactin (PRL) 
• corticotrophs, which produce and secrete adrenocorticotropic hormone (ACTH) and 
other pro-opiomelanocortin peptides 
• gonadotrophs, which produce and secrete follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) 
• thyrotrophs, which produce and secrete thyroid-stimulating hormone (TSH). 
The anterior lobe also includes the folliculostellate cells, which are not hormone-secreting 
but which play an important role in the integration of information in the anterior pituitary 
auto/paracrine loops. 
 
Posterior lobe (neurohypophysis) (B) 
The posterior pituitary lobe is comprisesd of the distal axons of the magnocellular 
neurosecretory cells extending from the supraoptic and paraventricular nuclei of the 
hypothalamus. These cells synthesize the neurohypophysial neurohypophyseal hormones 
oxytocin and vasopressin and store them into neurosecretory granules at their axon 
terminals; from where they are released from here into the neurohypohyseal capillaries and 
the systemic circulation.  
 
Blood supply (B) 
The anterior pituitary receives most of its blood supply from the hypothalamo-hypophyseal 
portal system, which originates from the capillary plexus of the median eminence and 
superior stalk, derived from the superior hypophyseal arteries. Through this system, the 
hypophysiotrophic hormones are delivered to the hormone-producing cells of the 
adenohypophysis. The remainder of the blood supply is through via the pituitary capsular 
vessels, which that also originate from the superior hypophyseal arteries. The posterior lobe 
and the stalk are directly supplied with blood from the hypophyseal arteries. 
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 The venous drainage from both lobes is through the cavernous sinuses into the 
petrosal sinuses and the internal jugular veins. 
 
Pituitary tumours (A) 
Pituitary tumours constitute 10-–15% of intracranial neoplasms and are often discovered 
incidentally on imaging performed for an unrelated reason (pituitary incidentaloma). Their 
clinical features maycan result from local mass effects and/or hypersecretion.1  
The local mass effects depend on the size of the tumour and its anatomical position/ and 
extensions. Headache is usually the consequence of dural stretching. The neuro-
ophthalmological effects include visual field defects (usually bitemporal hemianopia) from 
compression of the optic pathways, and ocular nerve palsies caused by lateral extension to 
the cavernous sinuses. Erosion of the sellar floor maycan result in sinusitis, CSF rhinorrhoea, 
and meningitis. The anterior pituitary hormone deficits tend to occur in a specific order, with 
GH and gonadotrophins affected first, followed by ACTH and TSH. PRL secretion is the most 
resistant, and decreased levelconcentrations indicate severe pituitary damage.  
All patients with a pituitary mass should undergo testing for hypopituitarism and neuro-
ophthalmological evaluation. In cases ofWith pituitary adenomas, hormonal hypersecretion 
needs to be assessed. Careful neuroradiology review aiming to identify imaging features 
helpful for the differential diagnosis is also mandatory.  
 
Pituitary adenomas (B) 
Pituitary adenomas account for 90% of pituitary tumours and have a prevalence of 77.6 
cases/ per 100,000 inhabitants in the UK. They are benign lesions arising from 
adenohypophyseal cells and, based on their size, are classified as microadenomas (<10 mm 
in diameter) or macroadenomas (≥10 mm in diameter). They may hypersecrete hypophyseal 
hormones (functioning) or maycan be clinically non-functioning. Whilst Although mostthe 
majority is are sporadic, , they are in rare cases, they may be related withto hereditary 
syndromes, like such as multiple endocrine neoplasia type 1, Carney complex or familialr 
isolated pituitary adenomas.  
 
Non-functioning pituitary adenomas (C) 
Non-functioning pituitary adenomas (NFA): these comprise 15–37% of all pituitary 
adenomas and have a prevalence of 7-–22/ per 100,000 inhabitants. As they are not 
associated with hormonal hypersecretion, they usually escape early diagnosis, and are 
mostly recognized when they are large enough to exert pressure effects to on surrounding 
tissues; thus, at the time of detection, 67–90% of them are macroadenomas. Additionally, at 
diagnosis, 60-–85% of the patients have at least one pituitary hormone deficiency.  
First-line treatment for the macroadenomas is surgery, usually with theusing a trans-
sphenoidal approach; this, which aims to improve or resolve the mass effects on adjacent 
structures, and especially the optic pathways. Radiotherapy is maycan be offered as 
adjuvant treatment after surgery, aiming to prevent tumour regrowth. The management of 
regrown non-functioning pituitary adenomas NFAs includes observation, surgery, 
radiotherapy or a combination of surgery and radiotherapy. 
 
Functioning pituitary adenomas (C):  
Functioning pituitary adenomasthese release excessive amounts of active hypophyseal 
hormones into the systemic circulation, resulting in multiple clinical manifestations. 
Prolactinomas are the most prevalent hormone-secreting adenomas followed by GH-
producing, corticotroph, and thyrotroph adenomas. The clinical presentation, diagnosis and 
treatment of functioning adenomas depend on the type of hormone(s) secreted (Table 2).  
 
Formatted: Indent: First line:  1.25
cm
Formatted: Font color: Blue
Formatted: Font: Bold, Not Italic
Formatted: Indent: First line:  0 cm
Formatted: Font: Bold, No underline
Formatted: Font: Bold
Formatted: Indent: First line:  1.25
cm
Formatted: Font: Not Bold
Formatted: Font: Bold, No underline
Other sellar or parasellar masses 
 (B) 
 
Rathke’s cleft cysts (C):  
thesey are benign sellar and/or suprasellar lesions that arise from remnants of Rathke’s 
pouch.2 Their size varies, as well asdoes their content (ranging from a clear CSF CSF-like 
liquid to a thick mucoid material made up of cholesterol and protein). Patients with a 
Rathke’s cleft cyst usually present with symptoms of compression to of adjacent structures, 
although incidentally detected cases are also reported. Surgery is the treatment of choice in 
patients with symptomatic cysts. 
Other cystic lesions usually found in the suprasellar region include arachnoid, 
epidermoid, and dermoid cysts. 
 
Craniopharyngiomas:  (C) 
these are sellar/parasellar tumours that arise from embryonic remnants of Rathke’s pouch. 
They are commonly found during childhood and adolescence,.3 However, theybut can be 
also diagnosed at any age. They are usually large masses with suprasellar extension and can 
invade the third ventricle and other brain structures. On imaging, craniopharyngiomas are 
mostly often predominantly cystic and usually filled with a cholesterol-rich fluid; purely or 
predominantly solid or purely cystic masses can beare also detected. Another common 
finding The presence ofis calcifications inside the tumour is also another common finding.  
Patients with craniopharyngioma demonstrate many clinical features due toresulting 
from local tumour effects (headache, vomiting, papilloedema, visual field deficits) and due 
to dysfunction of the hypothalamus and pituitary (obesity, problems with appetite, satiety, 
temperature control, hypopituitarism). Treatment of these tumours involves hypothalamus-
sparing surgery followed by local radiation therapy. The long-term outcomes are not optimal 
due to thebecause of significant morbidities. 
 
Hypophysitis (C): this 
Hypophysitis is an inflammatory disease that can affect both lobes of the pituitary, as well as 
the stalk. The Diagnosis of this condition can be difficult given that 50% of the cases are 
misdiagnosed as pituitary adenomas (Table 3).  
 
Pituitary stalk lesions (C): 
 the spectrum of pituitary stalk is extensive, but can be considered  and is divided in three 
main categoriesunder three main headings:  
• neoplastic –: thesey account for the majority ofmost pituitary stalk lesions, with 
metastases (mainly from lung and breast cancer) and lymphoma being the most 
frequent, followed by germ cell tumors and astrocytomas. 
• inflammatory and infiltrative diseases–: hypophysitis is the most common cause, 
followed by neurosarcoidosis and Langerhanhs’ cell histiocytosis.   
• congenital conditions–: thesey constitute the minority of stalk lesions; pituitary 
hypoplasia and Rathke’s cleft cyst are the most frequent causes.  
Central diabetes insipidus and hyperprolactinaemia (absence of normal hypothalamic 
dopamine suppression of prolactin release due tocaused by stalk interruption) are the most 
commonest hormonal findings amongst patients with pituitary stalk lesions. Anterior 
hypopituitarism can also be observed. All patients should undergo clinical, biochemical, and 
imaging investigations, and if diagnosis remains unclear, then a pituitary stalk biopsy maycan 
be considered if the diagnosis remains unclear.4  
 
Other lesions (C):  
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Other less frequent sellar and /parasellar lesions include:  
• non-adenomatous tumours:  – meningiomas (comprising the majoritymost of this 
group), chordomas, gliomas and pituicytomas.  
• pituitary infections:  – haematogenous or local spread of infectious agents can result 
in pituitary abscess and perisellar arachnoiditis. 




Hypopituitarism is the result of conditions that reduce or destroy the pituitary function or 
interfere with the hypothalamic secretion of pituitary-releasing hormones, leading to a 
complete or partial deficiency in of pituitary hormones.5 
 
Etiology Aetiology(B)  
Apart from the space-occupying lesions of the pituitary, other conditions resulting in 
hypopituitarism include:    
• Vascular –: pituitary apoplexy oin the background of a pituitary tumour is the most 
frequent vascular cause of hypopituitarism. It can be a life-threatening condition 
that requires acute management (Table 4). On the other handIn contrast, 
postpartum ischaemic pituitary necrosis (Sheehan’s syndrome) is now relatively rare 
due tobecause of the advances in obstetric care.  
• Traumatic –: traumatic brain injury and subarachnoid haemorrhage may resultcan 
cause in hypopituitarism. 
• Iatrogenic:  – surgery and irradiation therapy for sellar/extasellar masses or brain 
tumours maycan compromise pituitary function. In addition, partial hypopituitarism 
may be seen as a result ofcan be caused various medications (glucocorticoids, 
opiates, etc.). 
• Congenital –: They canmaythese can manifest as be isolated deficiencies due 
tocaused by mutations in the genes coding for a specific hormone, or multiple 
deficiencies resulting from abnormal pituitary development (e.g. PROP1,, HESX1,  
and POU1F1 gene mutations). 
 
Clinical manifestation and diagnosis (B)  
The clinical features of hypopituitarism vary and depend on the rapidity of onset, the 
severity of the hormonal defect(s), and the number and type of hormones affected. The 
Establishingment of the diagnosis requires hormonal measurements (basal or after dynamic 
tests) (Table 5).  
 
Treatment (B) 
Hydrocortisone is the treatment of choice in central hypoadrenalism (usual total daily 
dosage of 15–20 mg divided into two or three doses). Patients should take the highest dose 
in the morning on at awakening and the second in the afternoon (two-dose regimen), or the 
second and third at lunch time and in the late afternoon,, respectively (three-dose regimen).  
Central hypothyroidism is managed with levothyroxine in doses sufficient to achieve 
serum free thyroxine levelconcentrations in the mid to upper half of the reference range, 
but and only after adequate hydrocortisone initiation (because thyroid hormone 
replacement maycan aggravate adrenal insufficiency in patients with untreated 
steroidcorticosteroid deficiency).    
Males Men and premenopausal females with central hypogonadism should be 
offered sex-steroid replacement therapy (provided there are no contraindications). Diabetes 
insipidus is managed with desmopressin, and GH deficiency with recombinant GH.     
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Table 1: Hormone-producing cells in the anterior pituitary gland 
 
Type of cell Percentage of cells in 
anterior pituitary lobe  
Distribution of cells 
Somatotrophs  40-–50% Lateral wings of 
adenohypophysis  
Lactotrophs 15–-20% Dispersed populations 
throughout the anterior 
lobe; mainly in the posterior   
part of the lateral wings  
Corticotrophs 15–-20% Middle and posterior portion 
of anterior lobe  
Gonadotrophs 10–-15% Distributed through anterior 
lobe 








• Females: – galactorrhoea, hypogonadism (oligo/amenorrhoea, and infertility) 
• Males:  – hypogonadism (impotence, decreased libido), galactorrhoea (very rare) 
Diagnosis 
• Hyperprolactinaemia (after excludingsion of macroprolactinaemia and of other 
causes of increased PRL levelconcentrations)  
• Immunoradiometric PRL measurement at a serum dilution of 1:100 in cases offor 
pituitary macroadenomas with normal or mildly elevated PRL values when the so-
called ‘hook effect’ is suspected (high levelconcentrations of circulating PRL causes 
antibody saturation in the immunoradiometric assay, leading to artifactually 
artefactually low results)  
Treatment 
• Medical therapy with dopamine agonists (cabergoline as first- line treatment, 
alternatively bromocriptine alternatively) 
• Surgery if there is resistance or intolerance to medical treatment  
• Radiotherapy in resistant or aggressive prolactinomas, usually after surgery 
GH-secreting adenomas  
Clinical features 
• Adults:  – acromegaly (acral enlargement, prognathism, frontal bossing, soft tissue 
overgrowth, hyperhidrosis, arthralgias, fatigue)  
• Children and adolescenceadolescents:  – gigantism    
Diagnosis 
• Serum IGF-1 levelconcentrations above the age-and sex-adjusted reference range  




• Medical therapy:  – somatostatin analogues, dopamine agonists, pegvisomant 
• Radiotherapy if no control of the disease is not controlled by surgery and medical 
treatment  
ACTH-secreting adenomas (Cushing’s disease) 
Clinical features 
• Cushing’s syndrome phenotype (weight gain and central obesity, skin thinning, 
purple striae, moon face, buffalo hump, proximal muscle weakness, spontaneous 
ecchymosis, increased supraclavicular fullness)  
Diagnosis 
• Endogenous hypercortisolism ([established by increased 24-hour urinarye free 
cortisol levelconcentrations, loss of diurnal rhythm of cortisol secretion (serum, or 
salivary), lack of serum cortisol suppression on overnight or low low-dose 
dexamethasone suppression test)]       
• Non-suppressed plasma morning   ACTH levelconcentrations 
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• CRH stimulation test, high high-dose dexamethasone suppression test, bilateral 
inferior petrosal sinus sampling 
Treatment 
• Surgery 
• Radiotherapy  
• Medical therapy:  – most commonly used with steroidogenesis inhibitors  
• Bilateral adrenalectomy 
TSH-secreting adenomas 
Clinical features 
• Hyperthyroidism  
Diagnosis 
• Non-suppressed TSH levelconcentrations in the presence of high FT4free T4 and, 
Ffree T3 concentrations 
• TRH stimulation test, T3 suppression test 
Treatment 
• Surgery 
• Medical therapy with somatostatin analogues (usually after non-curative surgery) 
• Radiotherapy if no control of the disease is not controlled by surgery and medical 
treatment 
Functioning gonadotroph adenomas  
Clinical features 
• Females:  – menstrual irregularities (oligo/amenorrhoea, spotting, menorrhagia), 
infertility, ovarian hyperstimulation syndrome (premenopausal women); no clinical 
syndrome in postmenopausal women 
• Males:  – testicular enlargement, hypogonadism 
Diagnosis 
• Females:  – hyperoestrogenism (occasionally normal or fluctuating oestrogen 
levelconcentrations); serum FSH levelconcentrations mildly elevated or within 
reference range; serum LH suppressed or less often within reference range 
• Males:  – serum FSH elevated; varying serum LH and testosterone 
levelconcentrations (slightly below the reference range, normal or elevated); 
increased sperm count may be seen 
Treatment 
• Surgery combined or not with radiotherapy 
In all cases, pressure effects of the adenoma to on surrounding structures from the 
adenoma may be seen.  
CRH: , corticotrophin-releasing hormone, ; (PRL: prolactin, GH: growth hormone, IGF-1: , 
insulin-like growth factor 1, ; ACTH: adrenocorticotropic hormone, TSH: thyroid-stimulating 
hormone, FFT3,: free  triiodothyronine; T4,: free thyroxine,, FSH: follicle-stimulating 




Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Formatted: Font: Not Italic
Table 3: Types, clinical features, imaging characteristics and treatment of hypophysitis 
 
Types of hypophysitis 
• Lymphocytic hypophysitis: , classically in women during or after parturition 
• Granulomatous hypophysitis 
• Xanthomatous hypophysitis 
• IgG-4 hypophysitis:  – in patients with IgG-4 4-related disease 
• Drug-induced hypophysitis (ipilimumab, nivolumab, pembrolizumab)  
Clinical features 
• Local tumour effects (headache, visual deterioration) 
• Anterior hypopituitarism 
• Diabetes insipidus 
Imaging characteristics 
• Symmetrical enlargement of the pituitary; stalk maycan be thickened, and 
suprasellar extension maycan be seen  
• A highly cystic lesion is often found in xanthomatous hypophysitis 
Treatment 
• High doses of glucocorticoids (although potential side eadverse effects should be 
carefully considered on an individual case basis) 
• Hormone replacement therapy in cases of hypopituitarism  
• Trans-sphenoidal surgery if visual deterioration and for histological confirmation of 
the diagnosis 
IgG, immunoglobulin G. 
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• Haemorrhage or infarction, usually on a background of a pituitary tumour 
• Precipitating Causative factors:  – hypertension, major surgery, coagulopathies, 
anticoagulation therapy, pregnancy, dynamic pituitary function testing, and head 
trauma 
Clinical presentation 
• Acute severe headache that maycan be accompanied by nausea and vomiting 
• Ocular nerve palsies, reduced visual acuity, visual field defects (usually bitemporal 
hemianopia) 
• Meningism (fever, neck stiffness, photophobia) 
• Altered consciousness  
Differential diagnosis 
• Subarachnoid haemorrhage 
• Meningitis (bacterial or viral) 
• Brainstem infarction 
• Cavernous sinus thrombosis 
Management 
• Supportive measures to ensure haemodynamic stability and careful monitoring of 
fluid and electrolyte balance  
• Immediate administration of high-dose glucocorticoids, especially in 
haemodynamically unstable cases or with severe neurological or neuro-
ophthalmological signs; thisit covers the increased risk of hypoadrenalism and has 
significant anti-inflammatory and anti-oedematous effects  
• Surgery is offered in the presence ofif there is severe visual acuity and visual field 
impairment (not isolated ophthalmoplegia), altered consciousness, deteriorating 
visual or neurological signs or of further enlargement of the sellar mass on serial 
imaging 
    
 
  
Table 5: Diagnosis of pituitary hormone deficits  
 
GH deficiency 
• GH stimulation testing is mandatory (insulin tolerance test, GHRH and arginine 
stimulation test, glucagon stimulation test)  
• Normal IGF-1 levelconcentrations does not exclude the diagnosis 
FSH/LH deficiency  
• Males –: low morning serum testosterone levelconcentrations (before 10:00 hours 
and ideally corrected for SHBG) and low or normal gonadotrophins  
• Females:  – low serum oestradiol levelconcentrations and low or normal 
gonadotrophins in the presence of oligomenorrhoea or amenorrhoea 
(premenopausal women); absence of high serum FSH and LH (postmenopausal 
women) 
ACTH deficiency  
• Serum cortisol levelconcentrations at 08:00–09:00 hours <100 nmol/L/litre (in the 
absence of steroidcorticosteroid administration) are indicative of adrenal 
insufficiency 
• If morning cortisol values are between 100– and 400 nmol/L/litre, a dynamic test 
(e.g. insulin tolerance test, glucagon stimulation test) is required to establish the 
diagnosis (eg. insulin tolerance test, glucagon stimulation test). The Cut-offs for 
serum cortisol need toshould be defined by each laboratory, but overall peak serum 
cortisol >500 nmol/L/litre at 30 or 60 minutes excludes the diagnosis 
Central hypothyroidism 
• Low free thyroxine levelconcentrations in conjunction with a low, normal, or mildly 
elevated TSH in the setting of pituitary disease 
Central diabetes inspidus 
• Confirm hypotonic polyuria – simultaneous measurement of serum/plasma and 
urine osmolarity in the presence of polyuria (>50 mLml/kg of body weight/24 
hours*).a) 
• Urine osmolarity >600 mOsmol/kg) effectively excludes the diagnosis of diabetes 
insipidus (urine osmolarity/plasma osmolarity ratio should be ≥2 during urine 
concentration); urine dipstick should be negative for glucose 
• Water deprivation test may also be needed 
a* Clinical correlation is important in this context (for examplee.g. hypotonic polyuria 
maycan also result following from the infusion of large volumes of intravenous fluids).  
(GH: growth hormone, GHRH: , growth hormone-releasing hormone, ; IGF-1: , insulin-like 
growth factor 1, ; FSH: follicle-stimulating hormone, LH: luteinizing hormone, ACTH: 
adrenocorticotropic hormone, TSH: thyroid-stimulating hormone, SHBG: , sex hormone-
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A 30-year-old woman was referred to Endocrinology the endocrine clinic withfor a one1-
year history of headaches, amenorrhoea and decreased libido. She had no visual 
deterioration. She hadThere was no significant past medical history, and she was not on 
taking any medication. Hormonal workupInitial i 
 
Investigations 
 •revealed Hypogonadotrophic hypogonadism, as well as increased  
•Serum prolactin levels (15,000 mU/L/litre, reference range (60-–620).  
•The Insulin-like growth factor 1IGF-1 and adrenocorticotrophic hormoneACTH reserve were 
normal  
•Thyroid function was normal and there was no hypothyroidism. She had no visual 
deterioration.  
•MR scan of the pituitaryPituitary MRI revealed a macroadenoma abutting, but not 
compressing, the optic chiasm. 
 
What is the best choice of treatment? 
A. Dopamine agonist 
B. Levothyroxine    
C. Pituitary radiotherapy 
D. Somatostatin analogue 
E. Trans-sphenoidal adenomeatectomy 
 
Correct answer: A.  
This patient has a macroprolactinoma. Dopamine agonists are the first-line treatment for 
this tumour, as they can lead tocorrect prolactin normalizationabnormalities, restoreation of 
gonadal function and lead to tumour shrinkage. Surgery (E) is an alternative option for 
patients who show resistance or intolerance to medical treatment. Radiation therapy (C) is 
used only in for resistant or /aggressive prolactinomas, and usually after surgery. 
Somatostatin analogues (D) are not effective in the treatment of prolactinomas, and 




A 45-year-old man was referred to the endocrine clinic for further assessment.  
ofEndocrinology due to a 3 cm pituitary mass, which had been  found on Iimaging, 
performed for headaches, had shown a 3 cm pituitary mass, likely to be a pituitary adenoma, 
occupying the sella, with suprasellar extension and invasion of the cavernous sinuses. ThHe 
patient had reported tiredness and low libido but no polyuria or polydipsia. The 
Nneuroradiologist reported that gy review suggested that the mass wasis most likely to be a 
pituitary adenoma, occupying the sella with suprasellar extenstion and invasion of the 
cavernous sinuses. There were no clinical manifestations of acromegaly, Cushing’s syndrome 
or hyperthyroidism.  
 
Investigations 
•Hormonal tests revealed IGF-1Insulin-like growth factor 1 below the reference range,  
•Hypogonadotrophic hypogonadism,  
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•ACTH Plasma adrenocorticotropic hormone 1.8 pmol/L/litre (3.3–15.4) and  
•TSH Serum thyroid-stimulating hormone 0.2 mU/L/litre (0.4–5.0) deficiency. There was no 
evidence of diabetes insipidus.  
 
What should be the first step in the patient’s management? 
A. Administer Ddesmopressin 
B. Growth hormone replacement therapy 
C. Hydrocortisone replacement therapy 
D. Levothyroxine replacement therapy 
E. Testosterone replacement therapy 
 
 
Correct answer: C.  
In patients with anterior hypopituitarism, hydrocortisone therapy should be initiated before 
any other hormonal replacement. Levothyroxine (D) should be offered after adequate 
hydrocortisone replacement is has been established, as otherwise, levothyroxine maycan 
otherwise aggravate adrenal insufficiency and lead to adrenal crisis. Growth hormone (B) 
and sex-steroid replacement therapy (E) can be offered later (provided there are no 




A 52-year-old man presented acutely with was admitted to the Emergency Department with 
acute headache, fever, confusion  and complainingts that light hurt his eyes., photophobia, 
and hypotension. His wife confirmed reported a 12 12-month history of tiredness and 
episodes of feeling lightheaded.  There was no history of polydipsia or polyuria. He had a 
history of is medical history included hypertension.  
On clinical examination, he was confused, with a temperature of T 38.0°0 C, HRheart rate 115 
beats/minminute, and BPblood pressure 102/68 mmHg. There was nNeck stiffness was 
identified noted on clinical examination. There were but no signs of ocular nerve palsies. The  
 
Investigations 
•Cerebrospinal fluidSF examination showedA lumbar puncture report revealed normal 
levelconcentrations of CSF protein, normal CSF:a plasma: glucose ratio and no presence of 
cells. CSF cCulture and Gram stain , as and well as  analysis for xanthochromia were 
negative.  
•Hormonal evaluation identified hypogonadotropic hypogonadotrophic hypogonadism,  
•Plasma adrenocorticotrophic hormone 1.6 pmol/L/litre (3.3–15.4)  
•Serum thyroid-stimulating hormone 0.3 mU/L/litre (0.4–5.0) ACTH and TSH deficiency. 
There was no evidence of diabetes insipidus.  
•MR scan of the brain Brain MRI showed a large pituitary tumour with signs of 
haemorrhage, but no other abnormalities. 
 
What is the most likely final diagnosis? 
A. Brainstem infarction 
B. Cavernous sinus thrombosis 
C. Meningitis  
D. Pituitary apoplexy 
E. Subarachnoid haemorrhage 
 
Correct answer: D.  
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This patient has developedhad a pituitary apoplexy on a background of a pituitary tumour. 
The normal results on CSF cerebrospinal fluid analysis results exclude the a diagnosis of 
meningitis (C) and subarachnoid haemorrhage (E). The fact that no cranial nerve palsies 
were noted, the absence of a history of central face or paranasal sinuses infection, and the 
negative findings oin the MRI eliminate the possibility of cavernous sinus thrombosis (B).   
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